In a breakthrough for cancer research, Medgnosis has leveraged its state-of-the-art generative AI (GenAI) system to transform drug discovery. This GenAI targets both druggable and undruggable proteins ...

Thomas Fuchs will lead artificial intelligence initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

ProPharma, a leading global provider of regulatory, clinical, and compliance services for the life sciences industry, is pleased to announce it has won the prestigious CPHI Pharma Award for Regulatory ...

The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

To enhance patient outcomes and increased trial success, Convert Pharma is leveraging companion AI- and genetic biomarkers, a ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics ...

Enovo is led by Mario Philips and his longtime colleague, Roel Gordijn. Mr. Philips and Mr. Gordijn collectively have over 50 years of leadership experience in the life sciences sector, including in ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.